Format

Send to

Choose Destination
Eur Arch Otorhinolaryngol. 2013 Feb;270(2):405-16. doi: 10.1007/s00405-012-2086-4. Epub 2012 Jun 30.

Human papillomavirus and oropharyngeal squamous cell carcinoma: what the clinician should know.

Author information

1
Department of Otolaryngology, Head and Neck Surgery, The Mount Sinai Medical Center, The Mount Sinai School of Medicine, One Gustave Levy Place, Box 1189, NewYork, NY, USA.

Abstract

The incidence of oropharyngeal squamous cell carcinoma (OPSCC) is rising in contrast to the decreasing incidence of carcinomas arising in other subsites of the head and neck. The human papillomavirus (HPV) infection has played an increasing role in these epidemiological changes and as the etiology for a significant fraction of head and neck squamous cell carcinomas, OPSCC in particular. Most importantly, many retrospective studies have shown that the prognosis differs significantly between patients with HPV-associated tumors and non-HPV associated tumors. Thus, questions arise on the choices of treatment for patients based on HPV status and the consequences of therapy. Given the recognized relevance of HPV status in OPSCC, many new questions concerning the biology, treatment, and prevention of HPV infection arise. This review is intended to highlight some of the major issues and frequently asked questions relevant for the clinician dealing with patients with OPSCC.

PMID:
22752642
DOI:
10.1007/s00405-012-2086-4
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center